Healthcare Innovation November 24, 2020
ASCO, Community Oncology Alliance oppose imposition of any mandatory demonstration projects on oncology practices, especially if they carry risk of harm to patients
Despite its stated goal of lowering drug costs, a new mandatory payment model from the outgoing leadership at the Centers for Medicare & Medicaid Services (CMS) is being panned by provider organizations and oncology associations. For instance, the Community Oncology Alliance called the so-called Most Favored Nation (MFN) drug-pricing model “brazen and unhinged.”
CMS recently announced the new payment model and issued a corresponding Interim Final Rule with Comment Period (IFC). Starting Jan. 1, 2021, the MFN Model will pay no more for high-cost Medicare Part B drugs than the lowest price that drug manufacturers receive...
Today's Sponsors
Today's Sponsor